Ajanta Pharma Limited CC-Dec23.pdf · 2024-01-31
It's really good to see that we are coming back to our 30%, almost 30% level. My first question is regarding our emerging market business. So, if I see correctly, we have launched about 20 products in 9 months and maybe 10 products this quarter itself. So, in that case, when we are launching so many products, why are we only expecting low double-digit growth in this market going ahead?
My second question is abo ut our Indian market share, but in our covered markets. So, we do give our IPM rankings, but we are obviously not present in all therapies. So, in our covered market, what is our market share or what is our IPM rank?